An Evaluation of the Safety of CSF-1 in Presbyopic Subjects
NCT ID: NCT05393895
Last Updated: 2025-06-11
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
178 participants
INTERVENTIONAL
2022-04-22
2022-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects
NCT04909450
Safety, Tolerability, and Efficacy of PresbiDrops (CSF-1), a Topical Ophthalmic Drug for Presbyopia
NCT02745223
Cyclosporine 0.05% Eye Drops for Vernal Keratoconjunctivitis Trial
NCT05353101
Safety and Efficacy of Licaminlimab Ophthalmic Solution for the Treatment of Dry Eye Disease
NCT05896670
Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-007)
NCT00548301
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CSF-1
One drop bilaterally twice daily for at least 6 weeks
CSF-1
One drop bilaterally twice daily for at least 6 weeks
Vehicle
One drop bilaterally twice daily for at least 6 weeks
Vehicle
One drop bilaterally twice daily for at least 6 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CSF-1
One drop bilaterally twice daily for at least 6 weeks
Vehicle
One drop bilaterally twice daily for at least 6 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
40 Years
64 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Orasis Pharmaceuticals Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Orasis Investigative Site
Newport Beach, California, United States
Orasis Investigative Site
Petaluma, California, United States
Orasis Investigative Site
Colorado Springs, Colorado, United States
Orasis Investigative Site
Danbury, Connecticut, United States
Orasis Investigative Site
Rock Island, Illinois, United States
Orasis Investigative Site
Overland Park, Kansas, United States
Orasis Investigative Site
Elizabeth City, North Carolina, United States
Orasis Investigative Site
Fargo, North Dakota, United States
Orasis Investigative Site
Cranberry Township, Pennsylvania, United States
Orasis Investigative Site
Kingston, Pennsylvania, United States
Orasis Investigative Site
Memphis, Tennessee, United States
Orasis Investigative Site
Cedar Park, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
21-150-0005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.